How to Invest in Multi-Billion Dollar Medical Psychedelics Industry

As the legal cannabis market booms, another class of drugs on the horizon is getting closer to legalization, with its own impending boom coming. And that means a whole new place for investment. So as MDMA, psilocybin, and DMT work their way through medical trials, here’s how to invest in this new medical psychedelics field.

Looking to learn more about Medical Psychedelics?
Subscribe to the Medical Cannabis Weekly Newsletter!

What are psychedelics?

Psychedelics are a subset of hallucinogenic drugs, which themselves are a subset of psychoactive drugs. Whether made in a lab like LSD, or found in nature like psilocybin or peyote, psychedelics are known for causing ‘trips’. When a person is tripping, they may have altered perceptions of the world around, experience/feel/taste/see/hear things that are not real (hallucinations), feel a heightened sense of connection to those around them, experience euphoria, feel a sense of spirituality and connectedness with the universe, and a greater sense of self-introspection. A large percentage of psychedelics are serotonergic, meaning they effect serotonin receptors in the brain, though they can do this in different ways.

Some drugs like DMT produce short trips of less than an hour in duration. While other drugs like LSD, psilocybin, and mescaline can cause trips that last for many hours, as many as eight or ten. Sometimes people experience bad trips in which negative, or even scary, hallucinations are experienced, and/or a rapid heartbeat, sweating, nausea, disorientation, and fatigue occur. There is indication that the majority of these symptoms can be controlled through proper dosing. In fact, many therapeutic psychedelic users consume the drugs in micro-doses.

All psychedelics are Schedule I in the Convention on Psychotropic Substances, a drug scheduling treaty which defines the legality of different compounds globally. Starting with the Staggers-Dodd bill in 1968 which illegalized LSD and psilocybin, and finishing with the placement in the Convention, making all such substances illegal to buy, sell, or consume, with no purported medical value.

psychedelics

Psychedelics have been used for thousands of years, all throughout the world, though their uses in medicine in the mid-1900’s, and proposed uses today, are generally different than the shamanistic/ritualistic way they were primarily used in history, although this is not to say that there were not traditions that did use psychedelics therapeutically. Technically, if a shaman is consuming ayahuasca to get rid of demons, I suppose that could be thought of as therapeutic anyway.

Medical psychedelics research

Psychedelics, particularly, LSD, were introduced to modern medicine around the 1950’s after Albert Hoffman synthesized the compound in Switzerland in 1938. Several psychotherapists at the time, like Humphry Osmond and Ronald Sandison caught onto the idea, bringing these treatments to England and America. Hoffman conducted, among other research and therapy, the Saskatchewan trials, and ultimately came up with the idea of ‘psychedelic therapy’ in which a single large dose of LSD was given along with therapy sessions.

‘Psycholytic therapy’ is what Ronald Sandison’s version became known as in the UK, with the difference being that Sandison’s treatment style was to do multiple sessions with smaller amounts of the drug that increased through the process. Both doctors found great success particularly with alcohol addiction. How much success? According to the Saskatchewan trials, as many as 40-45% of drinkers were still not drinking a full year after the therapy session.

Unfortunately, when the drugs were made illegal, all ability to continue such treatments ended, and the ability for research into the field was completely stymied, and did not pick up again until much more recently. However, to give an idea of the massive turnaround that has been going on when it comes to psychedelics, consider that the US’s Food & Drug Administration (FDA), singled out both psylocibin in 2019 and MDMA in 2017 as ‘breakthrough therapies’ for depression and PTSD respectively. Such a designation by the FDA is meant to speed up research and development for products deemed necessary for health.

This indicates a desire by a US government agency to not only test these drugs, but to get them to market. And they’re all schedule I right now. One exception to psychedelics all being schedule I, however, is magic mushrooms. Though its psychoactive components like psilocybin are Schedule I, and therefore illegal, the plants themselves are not outlawed, creating a bit of gray area in terms of mushroom use, cultivation, and production. This gray area could prove useful in the future.

What can be expected?

If you’re wondering why this matters, consider how massive – and growing – the legal cannabis markets are. Well, psychedelics offer many of the same medical benefits, especially psychologically, with possibly added abilities in other departments. And they’ve proven to be very safe. As an industry in which much of it is pharmaceutical to begin with, it’s a safe bet that these drugs are going to pick up quickly. Because the pharma world is sure to take a massive interest, it gives even more reason to invest in medical psychedelics now, before everything explodes.

psychedelic-assisted therapy

So how much is it worth? I’m not the kind of writer who generally likes to get into these numbers. Every publication makes its own predictions, off its own information, and very rarely do these predictions seem to consider world changes. Whatever the size of the CBD industry was originally predicted to grow to a few years ago, that number would be invalid by now because it didn’t account for THC-based medicines growing in popularity, or legal markets, or psychedelics.

Imagine how much psychedelics could eat away at cannabis revenue. And not only that, any predictions of the future market size for psychedelics would have to take into account the still expanding cannabis markets (with more countries constantly legalizing in some form or another), and the question mark of what currently unforeseen factors could upend the trend a few years down the line. So, I’m not concerned with too many predictor numbers, but here’s just one, in order to get an idea what we’re dealing with.

PRNewswire, citing an analysis by Data Bridge Market Research, explained the forecast for 2020-2027, in which the field is expected to grow to $6.8 billion by 2027. It was worth just over $2 billion in 2019.

Best ways to invest in growing medical psychedelics field

Now that a certain barrier seems to be broken, more companies are conducting clinical trials, getting patents, and starting to get clearances for products. In fact, if you thought the psychedelics market was off limits, you’d be very much mistaken. Not only is this a growing market with a lot of possibility, but companies are already staking their claim, leaving room for you to start investing. So, if you like the idea of getting in on something before it explodes, consider investigating the following companies, and invest in the medical psychedelics field.

Much like with cannabis, Canada is quickly establishing itself as a leader in medical psychedelics, with the top companies coming out of this country. In the first half of 2020, $150 million USD was raised by six different companies: Mind Medicine, COMPASS Pathways, Field Trip Psychedelics, ATAI Life Sciences, Orthogonol Thinker, and Numinous Wellness. Mindmed and Numinous are already publicly listed companies. This is an early stage entry for investors. In fact, to give an idea of how seriously Canada is taking this, the first exchange traded fund – The Horizons Psychedelic Stock Index ETF, made its debut in January. ETF’s are like regular asset exchanges, except that they include a mix of stocks, commodities, and bonds. This exchange is solely for psychedelics.

The CEO of the fund, Steve Hawkins, said that while larger pharmaceutical companies have been admitted to the fund, the idea is to keep it mainly for smaller psychedelics companies. Companies can be added to the fund if they can tick the following boxes: be a part of a regular US or Canada-based stock exchange, be a biotechnology company focusing on medical psychedelic research, be a producer and/or supplier of psychedelic medicines, and be a company that works within the general supply chain for psychedelic medications.

medical psychedelics

Biggest names so far

When it comes to emerging fields and investing, the majority of people will never get there preemptively, and will instead act by reaction. For anyone who wants to get in on it before the top blows off, the following companies currently provide the best prospect for future growth, expansion, approval, and ability for revenue. These names should be noted, they will likely be bringing you the first approved medical psychedelic products, and for anyone looking to invest in this rapidly growing field of medical psychedelics, they stand out as the best options so far.

Mind Medicine is one of the furthest along when it comes to getting a product out there. It’s a pharmaceutical company that specifically works to develop psychedelic medications. The company is currently in the middle of six different trials on drugs like MDMA, LSD and DMT. In January of 2021, MindMed announced the first ever clinical trials to involve a combination of MDMA and LSD, with company president Dr. Miri Halperin Wernli stating:

“I believe that when LSD and MDMA are taken together they have exceptional potential to open a window into our mind which will awaken it to new levels of awareness by changing the fluidity of the ‌state‌ ‌of‌ ‌consciousness, amplifying‌ ‌changed‌ ‌perceptions,‌ ‌intensifying ‌emotions‌, ‌and‌ stimulating ‌novel‌ ‌thoughts. It is like a gateway to a multidimensional universe.”

When it comes to MDMA trials, MAPS – Multidisciplinary Association for Psychedelic Studies,  is also making its way to approval. MAPS entered phase III of its trials into MDMA for PTSD, and aligned this phase with the FDA according to a Special Protocol Assessment made directly with the FDA. This means that so long as the trials show clinically significant results, the study will already check all FDA regulatory boxes, and make it that much easier for approval.

However, a psychedelic drug has technically already been approved by the FDA. In March of 2019, Johnson & Johnson’s Spravato got approval. The spray treatment is considered for those who have not received a benefit from at least two separate anti-depressants. Spravato is a drug that’s a chemical cousin of the drug ketamine, which is classified as a dissociative drug, but also as a psychedelic. The medication is meant for severe depression.

There are tons of companies popping up. Apart from the companies already listed, prospective investors should check out Champignon Brands, Hollister Biosciences, Better Plant Sciences, Captiva Verde Land, Core One Labs, Cybin, Empower Clinics, Ehave, Jazz pharmaceuticals and EGF Theramed Health. All of these companies are associated in some way or other with the production of psychedelic medications. And while I have yet to see it mentioned in an article, it seems to me that what might upend everything I just said, is the ability to cultivate magic mushrooms.

LSD

Something to consider

Much like cannabis, mushrooms come with the ability for easy self-cultivation, as well as large scale cultivation. People who invest in today’s cannabis cultivation already know the value of having growing fields. Imagine the same thing, but with mushrooms. I personally believe that the biggest way in the future to invest in medical psychedelics, will be through the growing of mushrooms.

As stated, this is my opinion, and has not been discussed much as far as I can tell. This is not shocking though, and really doesn’t mean much, as this topic is also an undesirable one for any biotech or pharmaceutical company that – much like with cannabis – would much prefer you know nothing about how to do this on your own. And much like cannabis, it’s easy enough to learn how for anyone who needs some help getting started. Plus, since cultivation and sale of the mushrooms themselves is actually legal in many places, it’s way more legal to grow a field of mushrooms in much of the world, than to grow a field of cannabis.

How to invest in Medical Psychedelics – Conclusion

That the medical psychedelics field is coming is not as much up for debate as many would believe. It might be growing in the shadow of the cannabis market, and being kept quiet until the ability for large scale monetization is possible, but it’s coming, and it will be big. For those who want to invest in the growing medical psychedelics field, getting in now is probably the best idea, and with all the new companies popping up every day, it’s sure to become a heated race very soon.

Hello and welcome to CBDtesters.co, the best location to get up-to-date cannabis-related news from around the globe. Join us frequently to stay in-the-loop on the exciting world of legal cannabis, and sign up for our newsletter so you always know what’s going on.

References

Why the Vape Ban Is Happening, and How It Will Impact Delta-8 THC
Florida Bill Aims to Legalize Medical Magic Mushrooms

DIY: How to Make Delta-8 THC at Home
Here is everything wrong with Biden’s “forced rehab” plan for drug reform
What is DELTA 8 THC (FAQ: Great resource to learn about DELTA 8THC)

Can LSD Treat Your Mental Illness?
Welcome to the World’s 1st DMT Trials into Depression
The CBD Flowers Weekly newsletter (your top resource for all things smokable hemp flowers). Delta 8 / 9 / 10 / 11… How Many THCs Are Out There?
The New Rise of Medical Psychedelics

The Delta 8 Weekly Newsletter (All you need to know about Delta 8 thc) and the Best Delta 8 THC Deals. How To Choose Delta-8 THC Flowers?
Ayahuasca In the Fight Against Drug Addiction The Many Faces of Tetrahydrocannabinol – Different Types of THC and Their Benefits Psychedelic-Assisted Therapy, and How It Works
Desert Tripping – A Closer Look at Peyote: Spiritual, Medicinal, & Controversial Nature’s Magic – The Health Benefits of Psilocybin Mushrooms

Disclaimer: Hi, I’m a researcher and writer. I’m not a medical professional, I have no formal legal education, and I’ve never been to business school. All information in my articles is sourced from other places, which are always referenced, and all opinions stated are mine, and are made clear to be mine. I am not giving anyone advise of any kind, in any capacity. I am more than happy to discuss topics, but should someone have a further question or concern, they should seek guidance from a professional in the relevant field for more information.

Yup, there’s a vape ban in the USA, but that doesn’t mean we can’t get you any delta-8 THC products at all. Delta-8 THC is the less psychoactive THC compound that produces less anxiety and panic for users. Check out the great delta-8 THC deals we’ve got, and start experiencing delta-8 in a whole new way.

The post How to Invest in Multi-Billion Dollar Medical Psychedelics Industry appeared first on CBD Testers.

Can LSD Treat Your Mental Illness?

For several decades, psychedelics have been uniformly outlawed, with massive campaigns from the late 1900’s used to raise fear and controversy over their effects. Now, as the world acclimates to the medical and recreational use of cannabis, psychedelics are being looked at once again for their medical benefits. In fact, one of the leading points of research is the use of LSD to treat mental illness.

When it comes to psychedelics, cannabis is one of the most popular, and its not hard to see why. THC has medical benefits and makes people feel good. However, for some people, regular THC is just too much. If you’re one of those people, check out our Delta-8 THC deals, and experience THC with slightly less psychoactive effect, and less anxiety.

What is LSD?

LSD, known more scientifically as Lysergic acid diethylamide, is a hallucinogenic psychedelic drug, which was first synthesized in 1938 by Swiss chemist Albert Hoffman. He was also the first person to experience its effects when he accidentally ingested a small amount in 1943. As a psychedelic, it is known for altering perception, feelings, and thoughts, as well as causing visions and sensations that are not actually there (hallucinations). LSD is in a class of drugs called ergolines which are often used to treat disorders like Parkinson’s. Unlike some compounds like DMT, LSD is manmade, though derived from the ergot fungus.

How exactly LSD works to cause the effects its associated with, is still not completely defined. However, certain aspects have been found in research. In one study put out in 2017 from the University of North Carolina, it was found that LSD interacts with serotonin receptors. Serotonin is a neurotransmitter that plays a big role in mood and brain communication. The particular receptor it effects is called 5-HT2AR. One of the interesting things that happens when LSD attaches to this receptor, is that the receptor closes over the molecule, preventing it from leaving quickly. This could very well explain why the drug can last for many hours, even after it has left the bloodstream.

The serotonin receptor it attaches to can activate two signaling pathways through G-proteins and β-arrestins within cells. With LSD, it primarily works through the β-arrestins. The researchers on this study found that different drugs in the ergoline group effect serotonin receptors differently, and found evidence that the compounds themselves can modify the structure of the receptor in order to activate different effects.

Research

There has actually been plenty of research into how LSD can aide in the treatment of mental illness. Back in 2014, a randomized, double-blind, placebo-controlled study was done to investigate how safe and effective LSD is in treating the anxiety experienced by patients with life-threatening illnesses.

12 patients were used in the study, and they were given drug-free psychotherapy sessions, along with two psychotherapy sessions with LSD. A two-month follow-up showed a positive trend according to the (STAI) State-Trait Anxiety Inventory in terms of reductions in trait and state anxiety. The reductions in anxiety related to the LSD were sustained for 12 months. No serious adverse effects were noticed, and minimal adverse effects subsided within one day. The overall outcome of the study was LSD safely decreased anxiety.

In a systematic review of LSD in psychiatry, 11 studies were identified  concerning LSD and mental health that consisted of randomized and controlled clinical trials. These were done between the years of 1950-1970 when it was not illegal to use LSD in medical testing, and when LSD was regularly studied for use with addiction, anxiety, depression, and psychosomatic diseases. As part of the 11 studies that made the cut, 567 subjects were administered LSD in doses of 20 to 800 micrograms. The overall finding was that LSD has positive results in psychiatric symptoms, particularly for alcoholism. A grand majority of the study authors from the review cited positive, if short-term, improvements. This was not always seen in long-term follow-ups.

LSD in the treatment of mental illness today

Yet another systematic review was done on studies into LSD from after 1970. This review, called the Modern Clinical Research on LSD was published in 2017. The review looked at five recent studies in London, Zurich and Basel. All studies were placebo controlled. The London studies were single-blind, non-randomized, the Switzerland studies were randomized, double-blind. In all studies, low-moderate doses of LSD were used between 40-80 micrograms. (It takes about 100-200 micrograms for a full LSD effect).

In terms of subjective effects according to validated psychometric scales, the response in controlled settings was mainly positive. Average group ratings for liking the drug and having positive effects reached 90% of the maximum possible on the VAS scale after 200 micrograms had been administered. At 200 micrograms, only a small percentage increase was made for the average of those who had a negative drug effect (<25%), however negative ratings did go up with the increase.

No high levels of anxiety or panic occurred, necessitating no sedation of patients to stave off negative effects. The main feelings experienced during testing were: bliss, altered perceptions, audiovisual synesthesia (think crossed wires and mixed-up responses), and derealization and depersonalization in positive ways. Higher doses included more insightfulness.

LSD for mental illness

In terms of the synesthesia, LSD produced spontaneous experiences, indicating it alters spontaneous processes, rather than creating an induced response. At under 100 micrograms, LSD promoted suggestibility, and at 200 micrograms it inspired mystical experiences during psychotherapy combined with LSD. Similar studies that have been done on psilocybin have shown that more intense mystical experiences are tied to long-term positive benefits.

However, these mystical effects were correlated at a high level with blissful states as well, meaning the long-term response could be more related to blissful experiences than mystical ones. In these studies, LSD promoted feelings of happiness, well-being, openness, closeness to other people, and trust.

In terms of negative effects, they generally didn’t last more than 10-24 hours, and included headache, difficulty with concentration, decrease in appetite, dizziness, dry mouth, nausea, exhaustion and feeling unbalanced. No severe adverse responses were noticed in any of the modern testing. LSD, in general, is considered non-toxic physically.

Why is it illegal?

When looking at all the positive scientific research, and the lack of detrimental side effects, it starts to look very strange that LSD has been illegalized, while pharmaceutical medications to treat the same things often have lower success rates and harsher side effects. While the US government might stick with a tagline of psychedelics being dangerous and having no medical value, there is another underlying story which makes a bit more sense.

LSD and psilocybin were first illegalized in the late 60’s after a years long smear campaign which coincided with the Vietnam war. America was off fighting a battle that didn’t technically involve it, and causing a massive death toll, and unspeakable and unnecessary violence and destruction to residents of Vietnam.

There was already a pretty heavy anti-war movement during that time. Want to speculate on how much bigger and harder to control that would’ve been if the country was focusing on the war as it should have been? The question of why America wanted to be in that war so badly is a whole debate in and of itself, but regardless of the ‘why’s, there are still some heavy truths. In 1994, a guy named John Ehrlichman, who had been the Assistant to the President for Domestic Affairs in Nixon’s administration, made this statement:

psychedelics

“The Nixon campaign in 1968, and the Nixon White House after that, had two enemies: the antiwar left and black people. You understand what I’m saying? We knew we couldn’t make it illegal to be either against the war or black, but by getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities. We could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news. Did we know we were lying about the drugs? Of course we did.”

Is it really any wonder that in 1968 the US passed the Staggers-Dodd bill illegalizing both LSD and psilocybin? Or that in 1971 the Convention on Psychotropic Substances treaty gave it a Schedule I ranking? And is it really any wonder that this was heavily pushed for by richer countries with developed pharmaceutical industries, while poorer countries that didn’t have industries that could benefit the same way, were against the illegalization?

What now?

Things can change easily from good to bad, but they can also change from bad to good. Growing scrutiny towards agencies like the DEA for blocking scientific discovery in order to restrict access, and a renewed interest in medical testing, has re-opened the door which had been closed on LSD. Last month, the company MindMed even announced the beginning of the very first clinical trial ever to incorporate LSD and MDMA to test the possible benefits in dealing with mental illness.

Mindmed is a biotech company specializing in medicines and therapies using psychedelics. The trials are being done in Switzerland, which has been the base for a lot of psychedelics testing. Considering it’s a biotech company doing them, the logic answer would be that they want to make a product to sell eventually. My guess is, by the time they’re ready, it’ll be more legal globally to make LSD products to treat mental illness. After all, think about how fast the cannabis industry changed in the last few years.

Conclusion

The ongoing legalizations of cannabis, which is also a psychedelic, though a much less intense one, do signal a change in things. LSD has shown a spectacular profile for aiding in mental illness, with so few adverse reactions, that its silly what people are taking instead. It’s hard to say what the future holds, but it might very soon be the legalization for LSD medically.

Welcome to CBDtesters.co, your primary spot for all cannabis-related news around the world. Stop by frequently to stay on top of the ever-changing world of legal marijuana, and sign up to our newsletter so you’re always in the know!

Resources

Cannabis and Schizophrenia – Not a Testable Hypothesis
Forced Legalizations: EU & France Battle it out Over CBD Laws

Is Delta-8 THC Legal? What Does The Law Says? Is CBD Effective for Treating Bipolar Disorder?
Everything You Need to Know About Kratom
What is DELTA 8 THC (FAQ: Great resource to learn about DELTA 8THC)

The New Italian Cannabis Contradiction
Merry Cannabis! Christmas and Marijuana
The CBD Flowers Weekly newsletter (your top resource for all things smokable hemp flowers). How to choose Delta-8 THC flowersDelta-8 THC Flowers: Everything You Need To Know.
The Medical Cannabis Weekly newsletter (International medical cannabis business report)
Relax: How CBD Can Reduce Anxiety
The Delta 8 Weekly Newsletter (All you need to know about Delta 8 thc) and the Best Delta 8 THC Deals.  Best Delta-8 THC Vape Bundles – Winter 2021 Gallup Poll Finds Americans Use CBD Mostly For Pain Management
Using CBG To Treat Clinical Depression The New Rise of Medical Psychedelics America Is Cannabis Friendly – It’s Official
A Complete Look At Cannabis and Depression
Will Cannabis Tourism Be Over in Amsterdam?   Compared to Prescription Medication, Medical Cannabis Not Always Affordable Alternative
CBD’s Role in the Treatment of Multiple Mental Health Disorders

The post Can LSD Treat Your Mental Illness? appeared first on CBD Testers.

Why Magic Mushroom Stocks are 2021’s New Pot Stocks

It’s not news that pot stocks gave investors some sweet returns in 2020, but not everyone got to the party on time. If you feel like you missed the boat on the cannabis boom. There might be an exciting new investment opportunity in the world of medicinal drugs in form of magic mushroom stocks. Although […]

The post Why Magic Mushroom Stocks are 2021’s New Pot Stocks appeared first on Latest Cannabis News Today – Headlines, Videos & Stocks.